JP2014506787A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506787A5
JP2014506787A5 JP2013552609A JP2013552609A JP2014506787A5 JP 2014506787 A5 JP2014506787 A5 JP 2014506787A5 JP 2013552609 A JP2013552609 A JP 2013552609A JP 2013552609 A JP2013552609 A JP 2013552609A JP 2014506787 A5 JP2014506787 A5 JP 2014506787A5
Authority
JP
Japan
Prior art keywords
nucleic acid
gne
expression construct
subject
acid expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013552609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506787A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/023536 external-priority patent/WO2012106465A2/en
Publication of JP2014506787A publication Critical patent/JP2014506787A/ja
Publication of JP2014506787A5 publication Critical patent/JP2014506787A5/ja
Pending legal-status Critical Current

Links

Images

JP2013552609A 2011-02-01 2012-02-01 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物 Pending JP2014506787A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438585P 2011-02-01 2011-02-01
US61/438,585 2011-02-01
PCT/US2012/023536 WO2012106465A2 (en) 2011-02-01 2012-02-01 Methods and compositions for increasing sialic acid production and treating sialic related disease conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017092571A Division JP2017158577A (ja) 2011-02-01 2017-05-08 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物

Publications (2)

Publication Number Publication Date
JP2014506787A JP2014506787A (ja) 2014-03-20
JP2014506787A5 true JP2014506787A5 (enExample) 2016-07-28

Family

ID=46603295

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013552609A Pending JP2014506787A (ja) 2011-02-01 2012-02-01 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物
JP2017092571A Pending JP2017158577A (ja) 2011-02-01 2017-05-08 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017092571A Pending JP2017158577A (ja) 2011-02-01 2017-05-08 シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物

Country Status (9)

Country Link
US (2) US20130030040A1 (enExample)
EP (2) EP3202425A1 (enExample)
JP (2) JP2014506787A (enExample)
KR (2) KR102257741B1 (enExample)
AU (2) AU2012212162A1 (enExample)
CA (1) CA2863578C (enExample)
IL (1) IL227773B (enExample)
MX (1) MX365095B (enExample)
WO (1) WO2012106465A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014031837A1 (en) * 2012-08-22 2014-02-27 The Regents Of The University Of California Compositions and methods for enhancing sialic acid levels in tissue
WO2014077863A1 (en) * 2012-11-19 2014-05-22 Nature Technology Corporation Replicative minicircle vectors with improved expression
US20140256639A1 (en) * 2013-02-14 2014-09-11 The Regents Of The University Of California Peptoid neutralizing agents
CN103088090B (zh) * 2013-03-01 2014-06-04 南京工业大学 一种n-乙酰葡萄糖胺异构酶在生产n-乙酰甘露糖胺中的应用
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
KR102765034B1 (ko) 2017-05-24 2025-02-11 유니버시타트 아우토노마 데 바르셀로나 섬유아세포 성장 인자 21 (ｆｇｆ21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
CN108285886A (zh) * 2018-01-30 2018-07-17 江南大学 重组枯草芽孢杆菌全细胞转化生产n-乙酰神经氨酸的方法
US11865165B2 (en) * 2018-09-18 2024-01-09 Daniel DARVISH GNE as a therapeutic agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173465A9 (en) 1995-10-11 2007-07-26 Monahan Sean D Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene
WO2001059075A1 (en) * 2000-02-08 2001-08-16 Genentech, Inc. Improved sialylation of glycoproteins
US20060218669A1 (en) * 2003-02-11 2006-09-28 Lokesh Joshi Sialylation of glycoproteins in plants
US20070073264A1 (en) * 2003-09-26 2007-03-29 The Trustees Of The University Of Pennsylvania Methods, compositions and apparatus for delivering heterologous molecules to cells
WO2008001023A1 (en) 2006-06-27 2008-01-03 Gigabeam Corporation Cellular communication system
EP2117304A4 (en) * 2007-02-07 2011-08-24 Gradalis Inc METHODS AND COMPOSITIONS FOR MODULATING SIALIC ACID PRODUCTION AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY
US9217020B2 (en) 2007-04-17 2015-12-22 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US9018174B2 (en) * 2008-05-28 2015-04-28 Hibm Research Group, Inc. Mouse model and treatment of hereditary inclusion body myopathy
CN102197131A (zh) 2008-09-09 2011-09-21 加利福尼亚大学董事会 通过代谢竞争除去污染性的非人唾液酸
US9045759B2 (en) * 2009-01-21 2015-06-02 James Arthur Williams DNA plasmids with improved copy number
WO2011096750A2 (en) * 2010-02-08 2011-08-11 Korea Advanced Institute Of Science And Technology Method for preparing recombinant glycoproteins with high sialic acid content

Similar Documents

Publication Publication Date Title
CN102718858B (zh) 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
CN102766204B (zh) 胰高血糖素样肽-1突变体多肽及其制备方法和其应用
JP2023071909A (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
JP2016516016A5 (enExample)
JP7598960B2 (ja) 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
JP2013534426A5 (enExample)
CN102643339B (zh) 一种glp-1类似物、制备方法及其应用
RU2019100525A (ru) Векторная система на основе аденоассоциированного вируса
UA126960C2 (uk) Похідна глюкагону
MX2013008948A (es) Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas.
JP2022500078A5 (enExample)
KR20230017804A (ko) Rhfgf21 융합 단백질, rhfgf21 융합 단백질을 인코딩하는 폴리뉴클레오티드, rhfgf21 융합 단백질을 포함하는 조성물, 및 rhfgf21 융합 단백질의 용도
JP2020514305A5 (enExample)
JP2022060514A (ja) ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療
EP3385285B1 (en) Fusion protein for á melanocyte stimulating hormone and preparation method and use thereof
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
JP2009507474A5 (enExample)
JP2013531681A5 (enExample)
CN100484957C (zh) 胸腺素β4衍生物及其应用
CN102181437A (zh) 猪脂联素球状结构域蛋白gAd基因及其编码的蛋白和应用
CN1288754A (zh) 提高饲料效率和家畜生长速度的基因处理
JP2018512874A5 (enExample)
JP2021533113A5 (enExample)
US20230295640A1 (en) Compositions and methods for controlling blood sugar levels using nanocapsule-based drug delivery system